No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 1 | 1 | 1 | 0 | N/A | N/A |
| Operating profit | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | $m | -0 | 0 | -0 | -0 | -0 | -1 | N/A | N/A |
| EPS reported | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | Locked | Locked | Locked |
| Environmental score | Locked | Locked | Locked |
| Social score | Locked | Locked | Locked |
| Governance score | Locked | Locked | Locked |
| Risk rating | Locked | Locked | Locked |
Company overview
CardioComm Solutions, Inc., established in 1989 and based in Toronto, Canada, specializes in developing advanced technological solutions for cardiac monitoring. The company delivers both sophisticated software and hardware products, as well as core laboratory reading services, specifically designed for electrocardiogram (ECG) and ambulatory arrhythmia detection systems. These comprehensive offerings cater to both the medical sector and individual consumers across the globe. At the heart of CardioComm's operations is proprietary technology that underpins the entire ECG workflow: from initial recording and seamless transmission to detailed viewing, in-depth analysis, comprehensive reporting, and secure long-term storage. This end-to-end capability is crucial for the effective screening, accurate diagnosis, and ongoing management of cardiac patients. Their unique device connectivity and ECG management platforms are integrated into diverse solutions, spanning general medical applications, consumer-grade health products, clinical research initiatives, and modern telemedicine services. The company's extensive software suite includes the Global ECG Management System (GEMS) for cardiac event monitoring, GlobalCardio 12 Lead—a web-enabled and EMR-compatible ECG device—and GEMS Lite for Windows, an electronic system for receiving ECG data. Complementary software modules further enhance their offerings, such as GEMS WIN Air for live wireless ECG monitoring, AutoAttendant to empower healthcare providers by automating routine tasks, and the GEMS HL7 Interface, which ensures compliant data exchange with other EMR systems. Additionally, GlobalCardio EMR integration facilitates the bi-directional transfer of crucial information, including patient data, reports, and related links. Beyond software, CardioComm provides a range of hardware products. These include the portable HeartCheck PEN and HeartCheck handheld ECG monitors, various Sirona telephonic and wireless event recorders, and the HeartCheck CardiBeat device. Furthermore, the company offers Application Service Provider (ASP) solutions, notably C4 ECG management services and HeartCheck SMART Monitoring. Their broader product portfolio also features GlobalCardio 3 Lead, the ECG Viewer SDK, QRS Diagnostic, and QRS 12 Lead Universal.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
CardioComm Solutions, Inc., established in 1989 and based in Toronto, Canada, specializes in developing advanced technological solutions for cardiac monitoring. The company delivers both sophisticated software and hardware products, as well as core laboratory reading services, specifically designed for electrocardiogram (ECG) and ambulatory arrhythmia detection systems. These comprehensive offerings cater to both the medical sector and individual consumers across the globe. At the heart of CardioComm's operations is proprietary technology that underpins the entire ECG workflow: from initial recording and seamless transmission to detailed viewing, in-depth analysis, comprehensive reporting, and secure long-term storage. This end-to-end capability is crucial for the effective screening, accurate diagnosis, and ongoing management of cardiac patients. Their unique device connectivity and ECG management platforms are integrated into diverse solutions, spanning general medical applications, consumer-grade health products, clinical research initiatives, and modern telemedicine services. The company's extensive software suite includes the Global ECG Management System (GEMS) for cardiac event monitoring, GlobalCardio 12 Lead—a web-enabled and EMR-compatible ECG device—and GEMS Lite for Windows, an electronic system for receiving ECG data. Complementary software modules further enhance their offerings, such as GEMS WIN Air for live wireless ECG monitoring, AutoAttendant to empower healthcare providers by automating routine tasks, and the GEMS HL7 Interface, which ensures compliant data exchange with other EMR systems. Additionally, GlobalCardio EMR integration facilitates the bi-directional transfer of crucial information, including patient data, reports, and related links. Beyond software, CardioComm provides a range of hardware products. These include the portable HeartCheck PEN and HeartCheck handheld ECG monitors, various Sirona telephonic and wireless event recorders, and the HeartCheck CardiBeat device. Furthermore, the company offers Application Service Provider (ASP) solutions, notably C4 ECG management services and HeartCheck SMART Monitoring. Their broader product portfolio also features GlobalCardio 3 Lead, the ECG Viewer SDK, QRS Diagnostic, and QRS 12 Lead Universal.